Longitudinal Imaging Patterns and Corticosteroid Management in COVID-19 Patients with Pre-existing ILD

Overview

This study analyzes the long-term imaging patterns and clinical outcomes of COVID-19 patients with pre-existing interstitial lung disease (ILD) over a 24-month period. It highlights the impact of corticosteroid management on disease progression and mortality in this high-risk population.

Background

Patients with pre-existing ILD are at significantly higher risk for severe outcomes from COVID-19, including increased ICU admissions and mortality. Understanding the long-term effects of COVID-19 on ILD is crucial for optimizing patient management and treatment strategies. This study aims to fill the knowledge gap regarding the structural consequences of COVID-19 in ILD patients, particularly concerning corticosteroid use.

Data Highlights

The study included 82 hospitalized COVID-19 patients with pre-existing ILD, monitored over 24 months with high-resolution CT imaging.

Key Findings

• COVID-19 significantly exacerbates underlying ILD, leading to increased risks of functional decline and mortality.
• Longitudinal imaging revealed progressive fibrotic changes in ILD patients post-COVID-19.
• Corticosteroid management strategies varied, with unclear optimal dosing impacting long-term outcomes.
• AI-assisted methods were employed to quantify HRCT changes over the study period.
• Patients with severe COVID-19 exhibited more pronounced structural lung changes compared to those with moderate illness.

Clinical Implications

Healthcare providers should closely monitor ILD patients recovering from COVID-19 for potential long-term complications. Tailoring corticosteroid therapy may be essential to mitigate progressive lung damage and improve survival outcomes in this vulnerable population.

Conclusion

The findings underscore the need for ongoing assessment of ILD patients post-COVID-19 and highlight the importance of corticosteroid management in influencing long-term disease trajectories.

References

1. European Radiology, 2024 -- Evaluating Radiologists' Ability to Differentiate Post-COVID-19 Lung Residuals from Interstitial Lung Disease Findings
2. European Radiology, 2024 -- Comparison of Ultra-Low-Dose and Standard-Dose Chest CT Imaging in Patients Experiencing Post-COVID-19 Symptoms
3. The Journal of Infectious Diseases, 2025 -- Corticosteroid Treatment and Long-Term Effects of Post-Infectious Inflammatory Response Syndrome in Non-HIV Immunocompromised Patients with Cryptococcal Meningitis
4. Impact of interstitial lung disease on COVID-19 severity: A nationwide register study, ScienceDirect
5. Clinical management of COVID-19: living guideline, June 2025, WHO
6. Intensive Care Medicine — Glucocorticoids Suppress Type I Interferon Beta Signaling and CD73 Expression in Human Lung Tissue
7. International Radiology Consensus Outlines Best Practices for Post-COVID CT | RSNA
8. Impact of interstitial lung disease on COVID-19 severity: A nationwide register study - ScienceDirect
9. Clinical management of COVID-19: living guideline, June 2025